EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort study

Yuki Etani iD, Yasutaka Okita iD, Yuichi Maeda iD, Kohei Tsujimoto iD, Makoto Hirao iD, Akira Onishi iD, Hideo Onizawa iD, Takaichi Okano iD, Keisuke Nishimura iD, Ayaka Yoshikawa iD, Hideyuki Shiba iD, Hideki Amuro iD und 12 weitere

Modern Rheumatology · 2025

DOI: 10.1093/mr/roaf029 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Yuki Etani und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, Suita, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinase Inhibitors, Antirheumatic Agents, Anti-Citrullinated Protein Antibodies. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We aimed to identify the impact of rheumatoid factor (RF) or anticyclic citrullinated peptide antibody (ACPA) titres on the retention of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis.

Methods

We retrospectively analysed 5312 courses of bDMARDs or JAKis from the ANSWER cohort. To calculate hazard ratios (HRs) for treatment discontinuation, we used multivariate Cox proportional hazards modelling, adjusted for potential confounders.

Results

HRs for discontinuation due to ineffectiveness were calculated based on RF classification, revealing that anti-interleukin-6 receptor (aIL-6R) antibodies exhibited the highest retention rates regardless of RF titre. In the RF-positive group, tumour necrosis factor inhibitors (TNFis) showed lower retention rates, whereas cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig) and JAKis followed aIL-6R in the retention rates. When classified based on ACPA, aIL-6R also exhibited the highest retention rates across all ACPA groups. TNFis showed lower retention rates compared with other agents in the ACPA-positive group, whereas CTLA4-Ig showed lower retention rates in the ACPA-negative group compared with other agents.

Conclusions

Considering effectiveness, aIL-6R showed the highest retention rates regardless of seropositivity. Although CTLA4-Ig and JAKis followed aIL-6R in RF or ACPA-positive cases, CTLA4-Ig showed the lowest retention rates in ACPA-negative cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidJanus Kinase InhibitorsAntirheumatic AgentsAnti-Citrullinated Protein AntibodiesBiological ProductsRheumatoid FactorHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTreatment OutcomeAdult

Stichwörter der Autor:innen

Anticyclic citrullinated peptide antibodyJanus kinase inhibitorsbiological disease-modifying antirheumatic drugsrheumatoid factor

Substanzen

Janus Kinase InhibitorsAntirheumatic AgentsAnti-Citrullinated Protein AntibodiesBiological ProductsRheumatoid Factor

Autor:innen und Institutionen

  • Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, Suita, Japan.
  • Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Department of Orthopedic Surgery, Osaka Minami Medical Center, Kawachi-Nagano, Japan.
  • Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki, Japan.

ORCID-Profile: Yuki Etani, Yasutaka Okita, Yuichi Maeda, Kohei Tsujimoto, Makoto Hirao, Akira Onishi, Hideo Onizawa, Takaichi Okano, Keisuke Nishimura, Ayaka Yoshikawa, Hideyuki Shiba, Hideki Amuro, Yonsu Son, Motomu Hashimoto, Tadashi Okano, Ryota Hara, Wataru Yamamoto, Shotaro Tachibana, Shinya Hayashi, Takaaki Noguchi, Atsushi Kumanogoh, Seiji Okada, Ken Nakata, Kosuke Ebina

Zitieren

APA

Etani, Y., Okita, Y., Maeda, Y., Tsujimoto, K., Hirao, M., Onishi, A., Onizawa, H., Okano, T., Nishimura, K., Yoshikawa, A., Shiba, H., Amuro, H., Son, Y., Hashimoto, M., Okano, T., Hara, R., Yamamoto, W., Tachibana, S., Hayashi, S., …, & Ebina, K. (2025). Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf029

Vancouver

Etani Y, Okita Y, Maeda Y, Tsujimoto K, Hirao M, Onishi A, et al. Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort study. Modern Rheumatology. 2025. doi:10.1093/mr/roaf029

BibTeX
@article{Etani2025,
  author = {Etani, Yuki and Okita, Yasutaka and Maeda, Yuichi and Tsujimoto, Kohei and Hirao, Makoto and Onishi, Akira and Onizawa, Hideo and Okano, Takaichi and Nishimura, Keisuke and Yoshikawa, Ayaka and Shiba, Hideyuki and Amuro, Hideki and Son, Yonsu and Hashimoto, Motomu and Okano, Tadashi and Hara, Ryota and Yamamoto, Wataru and Tachibana, Shotaro and Hayashi, Shinya and Noguchi, Takaaki and Kumanogoh, Atsushi and Okada, Seiji and Nakata, Ken and Ebina, Kosuke},
  title = {Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort study},
  journal = {Modern Rheumatology},
  year = {2025},
  doi = {10.1093/mr/roaf029}
}
Kostenlos starten →